Search Results
Your search for it matches 15453 pages
Showing 5751 - 5800Is Nonmetastatic Castration-Resistant Prostate Cancer a Valid Disease Category?
Does nonmetastatic castration-resistant prostate cancer really exist? Although it is considered a disease category, it turns out that the definition depends on the type of imaging used. Many patients with castration-resistant prostate cancer who were categorized as “nonmetastatic” on conventional...
Role of Integrative Therapies for Patients With Colorectal Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Richard T. Lee, MD, describes the symptoms associated with colorectal cancer...
‘Unexpected’ Survival Benefit With Trilaciclib Plus Chemotherapy in Triple-Negative Breast Cancer
An unanticipated result of a randomized phase II study was the improvement in overall survival achieved with the investigational CDK4/6 inhibitor trilaciclib in women with metastatic triple-negative breast cancer. The drug was not being evaluated for its anticancer effects, but rather as a means of ...
RSNA 2019: MRI-Guided Ultrasound Treatment for Localized Prostate Cancer
A novel magnetic resonance imaging (MRI)-guided procedure that uses therapeutic ultrasound may effectively treat prostate cancer with minimal side effects, according to a new study presented at the 2019 annual meeting of the Radiological Society of North America (RSNA) (Abstract SSC07-07)....
RSNA 2019: High-Dose Brachytherapy for Older Patients With Nonmelanoma Skin Cancer
High-dose brachytherapy for elderly patients with nonmelanoma skin cancer produces excellent cure rates and cosmetic outcomes, according to a new study presented at the 2019 annual meeting of the Radiological Society of North America (RSNA) (Abstract SSM24-02). “For elderly patients [with...
Checkpoint Inhibitor Pneumonitis: A Pulmonologist’s Perspective
Oncologists have become accustomed to seeing pneumonitis associated with immune checkpoint inhibitor treatment in non–small cell lung cancer (NSCLC), requiring intervention by pulmonologists in the management of severe cases. At CHEST 2019, the annual meeting of the American College of Chest...
Biomarker-Driven Treatment Selection for Prostate and Other Genitourinary Cancers
As the Nobel Laureate Bob Dylan wrote, “The times they are a-changin’.” Heather Cheng, MD, PhD, Associate Professor, University of Washington, Associate Member, Fred Hutchinson Cancer Research Center, and Director, Seattle Cancer Care Alliance, Prostate Cancer Genetics Clinic, quoted this line in...
Immunotherapy Strategies in Renal Cell Carcinoma: Present and Future
Immunotherapy with checkpoint inhibitors is now considered a standard of care for the front-line treatment of advanced renal cell carcinoma. Despite better outcomes with these agents, there is still room for improvement. At the 2019 Chemotherapy Foundation Symposium, Robert J. Motzer, MD, of...
Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer
In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...
Cardiovascular Disease Risk May Be Associated With Cancer Risk
People with risk factors for cardiovascular diseases (determined by traditional risk, 10-year artherosclerotic cardiovascular disease risk score, and biomarkers) were also at higher risk for developing cancer compared to people with lower cardiovascular disease risk, according to research presented ...
Associations of Oncotype DX Breast Recurrence Score With Mortality Prediction and Difference Between Sexes
A study comparing the prognostic value of the Oncotype DX Breast Recurrence Score in male and female patients with early-stage estrogen receptor (ER)-positive breast cancer has found that the score is associated with mortality in male patients at a much lower threshold than female patients. The...
Assessing Cancer Pain Management in the Era of the Opioid Epidemic
A vast majority of patients with cancer receiving opioids for the management of pain will adhere to the opioids as prescribed and will have no major difficulties with dose reduction and even treatment discontinuation if the pain syndrome resolves. However, about 20% of patients with cancer are at...
How the PROMISE Study Aims to Convert Multiple Myeloma Into a Preventable Cancer
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called (PROMISE; ClinicalTrials.gov identifier NCT03689595) to identify people with premalignant precursor conditions of multiple myeloma, to understand the molecular signs of progression to myeloma...
Geriatric Assessment–Guided Multidisciplinary Care May Benefit Older Patients Undergoing Stem Cell Transplantation
Older adults with blood cancers may benefit from a team-based, holistic evaluation before undergoing transplantation, according to a study published by Derman et al in Blood Advances. The study, which reported on a multidisciplinary clinic at the University of Chicago Medical Center, found that...
DUOX2 Mutation in Familial Thyroid Cancers
Researchers have identified a new genetic mutation that may cause a type of familial thyroid cancer. According to the researchers, DUOX2 is the first and only mutation associated with familial thyroid cancer to be identified in a gene that is primarily expressed in the thyroid gland. These findings ...
Activity of Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or With Nivolumab in Advanced Solid Tumors
In a phase I/IIa study reported in JAMA Oncology, Lillian L. Siu, MD, FRCPC, FASCO, and colleagues found no evidence of activity of the glucocorticoid-induced tumor necrosis factor (TNF) receptor–related protein (GITR) agonist antibody BMS-986156 alone or in combination with nivolumab in patients...
FDA Pipeline: Recent Designations in Hepatocellular Carcinoma, Cholangiocarcioma, Lymphoma, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) granted reviews or designations to treatments for gastrointestinal cancers and lymphoma, and also provided authorizations for products designed to screen for malignancies and tumor mutational burden. Priority Review for Nivolumab...
Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
In the phase III trial Gynecologic Oncology Group (GOG)-0213 trial, reported in The New England Journal of Medicine by Robert L. Coleman, MD, and colleagues, no overall survival benefit was found for secondary surgical cytoreduction followed by chemotherapy vs chemotherapy alone in women with...
ESMO Asia 2019: Trastuzumab Biosimilar HLX02 Shows Activity in HER2-Positive Metastatic Breast Cancer
The trastuzumab biosimilar HLX02—manufactured in China—achieved a similar overall response rate to reference trastuzumab in women with HER2-positive recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported by Xu et al at the European...
Updated Data From Clinical Trials on Nivolumab/Ipilimumab in Advanced Melanoma
More than one out of two patients with metastatic melanoma treated with the combination of nivolumab plus ipilimu-mab is still alive after 5 years, according to the longest follow-up of patients receiving this combination. In two additional studies, the immunotherapy duet also proved to be active...
MSKCC Awards Young Investigators 2019 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) has named three investigators as the recipients of this year’s Paul Marks Prize for Cancer Research. The award recognizes scientists for their accomplishments in the area of cancer research. The winners for 2019 are Nathanael S. Gray, PhD; Joshua...
Your Stories: Behind the Breakthroughs
When Desirée Walker was diagnosed with breast cancer, she considered not treating it—but more frightening to her than the side effects of chemotherapy was missing the chance to watch her children grow. In “Mother Knows Best”—part of the Your Stories Featured Conversations series from Conquer...
ASCO President-Elect Candidates Discuss Key Issues in Oncology
Patrick J. Loehrer, MD, FASCO, of the Indiana University Melvin and Bren Simon Cancer Center, and Everett E. Vokes, MD, FASCO, of the University of Chicago Medicine Comprehensive Cancer Center, were selected by the ASCO Nominating Committee as candidates for President-Elect. Below, they discuss...
Breast Cancer Research Foundation Honors Eric Winer, MD, With Jill Rose Award
Eric Winer, MD, Director of the Breast Oncology Program at Dana-Farber Cancer Institute was recognized earlier this month with The Jill Rose Award from the Breast Cancer Research Foundation (BCRF). This honor is given annually to a researcher in recognition of pioneering research in their...
Using the Nobel Prize to Champion Curiosity-Driven Research in Cancer
William G. Kaelin, Jr, MD, Sidney Farber Professor of Medicine and Howard Hughes Medical Institute Investigator at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, admits that early in his research career, he and his late wife, Carolyn, would have fun...
When to Consider Local Therapy for Stage IV Breast Cancer
Local therapy for stage IV breast cancer has not been proven to increase overall survival, yet there are some cases where local therapy could be considered outside a clinical trial. For patients with intact asymptomatic primary tumors, local therapy could be offered if distant disease is well...
A Diagnosis of Multiple Myeloma Taught Me to Live in the Moment
I was just 39 in 2015 when I was diagnosed with multiple myeloma. I have a wife and three young children whom I love, a challenging and fulfilling career, and I wasn’t ready to die. When I was first diagnosed, I met with a medical oncologist who had little experience treating this type of cancer....
MD Anderson and University of Puerto Rico Receive $13 Million Grant Renewal
The University of Texas MD Anderson Cancer Center and the University of Puerto Rico received a competitive renewal of their Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) grant from the National Cancer Institute. The CPACHE grant provides a total of $13 million over 5 years....
Expert Point of View: Oreofe Olukemi Odejide, MD, MPH
Discussant of the abstract by Rao et al, Oreofe Olukemi Odejide, MD, MPH, a medical oncologist at Dana-Farber Cancer Institute, Boston, underscored the issues associated with intense health-care utilization near the end of life. “Several studies have shown that intense health-care utilization...
Oncology Clinicians Play A Role in Telling Patients About the Importance of Exercise
New exercise guidelines for patients with cancer can “improve physical and psychological outcomes from cancer diagnosis and for the balance of life,” concluded representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control.1 Attention...
Despite Challenges, Pioneer in CT Screening for Early Lung Cancer Works to Move the Field Forward
In 1999, a team of researchers from Weill Cornell Medical College advocated the use of a then-novel practice: low-dose radiation CT screening for lung cancer. It captures a full thoracic image in a single breath hold, and can recognize a tumor in its earliest stages when the chance for cure is...
A Call to Action for Oncology Clinicians to Help Patients ‘Move Through Cancer’
“There is clear evidence that patients are more likely to exercise if their oncologist tells them to do so,” reported representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control. In an article published in CA: A Cancer Journal for...
University of Michigan Cancer Programs Receive $9.2M Grant for Prostate Cancer Research
Two Michigan cancer programs are joining forces to find new solutions for prostate cancer. The University of Michigan (U-M) Rogel Cancer Center and the Barbara Ann Karmanos Cancer Institute at Wayne State University have received a $9.2 million grant from the National Cancer Institute (NCI). The...
Calaspargase Pegol-mknl for Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia
In late 2018, calaspargase pegol-mknl, an asparagine-specific enzyme, was approved for use as a component of a multiagent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years.1,2 The new product provides for a longer interval ...
The Anesthesia Era: 1845–1875
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and...
Trifluridine/Tipiracil in Recurrent, Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Early in 2019, trifluridine/tipiracil tablets were approved for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine; a platinum; either a taxane or...
Expert Point of View: Charles L. Loprinzi, MD
Charles L. Loprinzi, MD, Regis Professor of Breast Cancer Oncology at the Mayo Clinic, in Rochester, Minnesota, discussed the abstract on oncology massage to treat chemotherapy-induced peripheral neuropathy. He said that although massage therapy shows promise for this patient population, its...
Thomas Gajewski, MD, PhD, Receives 2019 ESMO Award for Immuno-Oncology
The European Society for Medical Oncology (ESMO) has selected Thomas Gajewski, MD, PhD, to receive the 2019 ESMO Award for Immuno-Oncology. The award is given in recognition of his groundbreaking work elucidating why some patients are resistant to immunotherapy and how to restore the anticancer...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
Elotuzumab in Combination Therapy for Previously Treated Multiple Myeloma
In late 2018, elotuzumab was approved for use in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.1 Supporting Efficacy Data Approval was based ...
Expert Point of View: Marleen Kok, MD
“This is currently the largest data set with information on retreatment,” said formal study discussant Marleen Kok, MD, of the Netherlands Cancer Institute, Amsterdam, The Netherlands. She noted there was a partial response in 11% and stable disease in 60%. “Upon initial treatment, partial...
An Oncologist’s Thoughtful Examination of Cancer and Personal Loss
“I could not have written this book when I was 30 years old. It is not because of any great discoveries I have made or research papers I have published since. It is because of the experience the intervening decades have given me as I cared for thousands of cancer patients and accompanied many to...
Physicians Should Lead by Example to Combat the Obesity Epidemic
American patients are suffering from an obesity crisis, where it is estimated that 300,000 deaths per year are due to obesity.1 The obesity trend is predicted to worsen, where it is projected that 85% of U.S. adults will be overweight or obese by 2030.2 Consequently, obesity-related illnesses are...
Navneet S. Majhail, MD, MS, Was Inspired by His Father’s Career as a Military Doctor and His Mother’s Battle With Cancer
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Navneet S. Majhail, MD, MS, about his journey from India to the Cleveland Clinic, where he is Director of the Blood and Marrow Transplant Program. He is also President of the American Society for...
Addressing the Obesity Epidemic and Barriers to Implementing Weight Management Programs for Cancer Survivors
Earlier this year, ASCO published the results of its new study on oncologists’ perceptions and practice behaviors regarding obesity, weight management, and related lifestyle factors in their patients both during and after cancer treatment.1 The findings from the online survey of 971 oncology...
Expert Point of View: Ian Chau, MD
The invited discussant for the ATTRACTION-3 study was Ian Chau, MD, Consultant Medical Oncologist at The Royal Marsden Hospital, London and Surrey, United Kingdom. Dr. Chau first congratulated the investigators for successfully conducting a randomized phase III trial in metastatic esophageal...
With a Little Help From My Friends: Social Support Linked to Pain Reduction in Patients With Cancer
Pain may be one of the most common symptoms experienced by patients with cancer, but researchers are still unpacking its mysteries, with some surprising results. According to data presented at the 2019 Supportive Care in Oncology Symposium,1 greater social support may help mitigate pain in patients ...
Nivolumab vs Chemotherapy in Advanced Esophageal Cancer
Nivolumab improved overall survival compared with chemotherapy in previously treated patients with esophageal squamous cell carcinoma in the final analysis of the phase III ATTRACTION-3 study. The data were presented at the European Society for Medical Oncology (ESMO) Congress 2019 Presidential...
ASCO Provides Guidance on Managing Osteoporosis in Cancer Survivors
Cancer survivors are at an increased risk of osteoporotic fractures due to the accelerated loss of bone mineral density as a result of their treatment. Bone loss from cancer therapy is faster and more severe than bone less from aging; rates of bone loss are up to sevenfold higher when they occur...
Affirming Universal Health Care as a Fundamental Human Right
This year’s meeting of the World Cancer Leaders’ Summit: Cancer and Universal Health Coverage, held on October 15–17 in Nur-Sultan, Kazakhstan, brought together more than 350 global health leaders, including ministers of health, first ladies, and industry leaders, from 82 countries to discuss how...
